Celcuity Inc. Common Stock
CELC
$92.44
+0.48%
Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors, with its lead candidate gedatolisib, a kinase inhibitor of the PI3K/AKT/mTOR pathway, currently in Phase 3 trials for HR+/HER2- breast cancer. The company is a niche player in the oncology space, differentiated by its comprehensive PAM pathway inhibition and a robust clinical pipeline. The current investor narrative centers on the potential FDA approval of gedatolisib, as evidenced by recent news highlighting significant institutional investments and the stock's dramatic rise, though the company remains pre-revenue and faces high regulatory and clinical risk.…
CELC
Celcuity Inc. Common Stock
$92.44
Related headlines
Investment Opinion: Should I buy CELC Today?
Rating: Buy. The consensus Strong Buy (1.17) and average target of $163.54 imply 77.8% upside, supported by positive Phase 3 data and institutional conviction. The thesis hinges on FDA approval of gedatolisib, which could generate billions in revenue, but the stock is only suitable for risk-tolerant investors.
Sign up to view all
CELC 12-Month Price Forecast
The AI model leans bullish due to strong clinical data and analyst conviction, but confidence is medium given binary regulatory risk. The stock's 43% drawdown from highs suggests market skepticism, yet the upside to analyst targets is compelling. A positive FDA decision would likely trigger a rally toward $150-178, while a rejection could halve the stock. The stance would upgrade to high confidence if additional positive trial data emerges or if FDA filing is accepted with priority review.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Celcuity Inc. Common Stock's 12-month outlook, with a consensus price target around $160.64 and implied upside of +73.8% versus the current price.
Average Target
$160.64
0 analysts
Implied Upside
+73.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$140 - $178
Analyst target range
Celcuity is covered by 11 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.17). The average target price is $163.54, implying a 77.8% upside from the current price of $92.00. The target range is $148.00 to $178.00, with the low target still 60.9% above the current price, indicating that even the most bearish analyst sees significant upside. The high target of $178.00 assumes successful FDA approval and commercial launch of gedatolisib, while the low target likely prices in some clinical or regulatory setbacks. Recent ratings actions have been overwhelmingly positive, with multiple firms reiterating Buy or Overweight ratings, and one upgrade from Neutral to Buy in May 2026, reflecting growing confidence in the drug's approval prospects.
Bulls vs Bears: CELC Investment Factors
Celcuity presents a classic high-risk, high-reward biotech profile. The bull case rests on strong analyst conviction, positive Phase 3 data, and institutional backing, while the bear case highlights pre-revenue status, extreme valuation, and binary regulatory risk. Currently, the evidence slightly favors the bulls given the strong buy consensus and 77.8% upside, but the tension between pipeline potential and financial sustainability is the key debate. The stock's fate hinges on FDA approval of gedatolisib; success could drive shares to $178+, while failure could send them below $44.42.
Bullish
- Strong Buy consensus with 77.8% upside: 11 analysts rate CELC a Strong Buy (mean 1.17) with an average target of $163.54, implying 77.8% upside from $92.00. Even the low target of $148.00 is 60.9% above current price, indicating rare analyst conviction.
- Phase 3 VIKTORIA-1 data positive: The Phase 3 trial for gedatolisib in HR+/HER2- breast cancer completed enrollment and reported positive results for PIK3CA WT tumors, a key efficacy signal. This de-risks the lead asset and supports FDA approval odds.
- Institutional conviction with large bets: A fund made a $170 million investment in CELC, and another added $17 million, creating top positions. Such high-conviction institutional buying often precedes major catalysts and signals informed confidence.
- Low beta of 0.2 provides stability: With a beta of 0.2, CELC is less sensitive to broad market swings, offering a hedge in volatile biotech portfolios. This low correlation can reduce portfolio drawdowns during market stress.
Bearish
- Pre-revenue with widening losses: Q1 2026 net loss widened 43% YoY to -$52.8M, with R&D and G&A expenses rising sharply. Zero revenue means the company is entirely dependent on external capital and clinical success.
- Extreme valuation at 52.1x book: PB ratio of 52.1x is astronomically high, reflecting market pricing of pipeline potential rather than assets. Any clinical setback could trigger a severe de-rating.
- Recent 43% drawdown from highs: Stock fell from $151.02 high to $92.00, a -43.25% max drawdown, indicating high volatility and profit-taking. The 3-month price change of -33.2% shows momentum has reversed sharply.
- High short interest at 5.94 days: Short ratio of 5.94 suggests significant bearish positioning, which could amplify downside if negative news hits. Short sellers may be betting on FDA rejection or trial failure.
CELC Technical Analysis
The stock has exhibited a strong uptrend over the past year, with a 1-year price change of +77.3%, but has recently pulled back significantly. As of August 14, 2026, the current price of $92.00 sits at 45.3% of its 52-week range (low $44.42, high $151.02), indicating a substantial correction from its highs. This positioning suggests the stock is in a consolidation phase after a parabolic rise, with the price now closer to the lower end of its range, potentially offering a value opportunity if the long-term uptrend resumes.
Beta
0.20
0.20x market volatility
Max Drawdown
-43.3%
Largest decline past year
52-Week Range
$44-$151
Price range past year
Annual Return
+78.5%
Cumulative gain past year
| Period | CELC Return | S&P 500 |
|---|---|---|
| 1m | +4.6% | +4.0% |
| 3m | -29.4% | +5.3% |
| 6m | -12.6% | +12.6% |
| 1y | +78.5% | +20.1% |
| ytd | -8.1% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CELC Fundamental Analysis
Celcuity is a pre-revenue company, with zero revenue reported in the most recent quarter (Q1 2026) and all prior quarters, reflecting its clinical-stage status. The company's net loss widened to -$52.8 million in Q1 2026 from -$37.0 million in Q1 2025, a 43% increase, driven by higher R&D expenses ($33.1 million vs. $32.2 million) and G&A costs ($17.4 million vs. $3.9 million). The trajectory of losses is increasing, indicating accelerating investment in clinical trials, which is typical for a late-stage biotech but raises concerns about cash burn.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-172930000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CELC Overvalued?
Given that Celcuity has negative net income and no revenue, the appropriate valuation metric is the price-to-sales (PS) ratio, but since revenue is zero, the PS ratio is undefined. Instead, we use the price-to-book (PB) ratio, which stands at 52.1x, and the EV/EBITDA at -33.0x, reflecting the company's lack of profitability. The forward PE is -557.6x, which is meaningless for a company with no earnings, but the negative value indicates the market is pricing in future profitability. The PB ratio of 52.1x is extremely high, suggesting the market is valuing the company's pipeline potential rather than its current assets.
PE
-26.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-33.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are substantial: Celcuity has zero revenue and a widening net loss of -$52.8M in Q1 2026, up 43% YoY. The company's cash burn is accelerating, with TTM free cash flow at -$172.9M, and debt-to-equity of 1.94 indicates leverage. While the current ratio of 10.5 provides near-term liquidity, the company will likely need to raise capital, causing dilution. The negative EV/EBITDA of -33.0x and PB of 52.1x leave no margin for error; any operational miss could trigger a funding crisis.
FAQ
The primary risk is clinical and regulatory failure, as a negative FDA decision or trial miss could cause a -50% or more decline. Financial risk is also high, with widening losses and cash burn of $172.9M TTM, requiring future dilution. Competitive risk comes from existing PI3K inhibitors and potential new therapies. Macro risk is low due to a beta of 0.2, but sector rotation away from biotech could pressure the stock. The most severe risk is a Complete Response Letter, which would likely send the stock to the 52-week low of $44.42.
Analysts forecast a 12-month target range of $148 to $178, with an average of $163.54, implying 77.8% upside. The bull case (35% probability) sees FDA approval and strong launch, pushing the stock to $150-178. The base case (45% probability) expects approval with a narrower label, leading to $120-150. The bear case (20% probability) involves rejection or trial failure, dropping the stock to $44-80. The most likely scenario is the base case, assuming FDA approval with some restrictions.
CELC is extremely overvalued on traditional metrics, with a PB ratio of 52.1x and negative PE, reflecting its pre-revenue status. However, biotech valuations are based on pipeline potential, not current earnings. The market is pricing in a high probability of FDA approval and significant future revenue, as evidenced by the $5.4B market cap. Compared to peers, the valuation is rich, but the potential market for gedatolisib could justify it if successful. The stock is fairly valued relative to its clinical progress, but any setback would expose overvaluation.
CELC offers a compelling risk/reward with 77.8% upside to the average analyst target of $163.54, but it is a pre-revenue biotech with high clinical risk. The stock is a good buy for investors who believe in gedatolisib's approval and commercial success, but it is not suitable for conservative investors. The biggest downside is a potential FDA rejection, which could send the stock to $44.42, a -52% loss. Given the strong analyst consensus and positive Phase 3 data, a speculative buy is justified for those who can tolerate volatility.
CELC is best suited for long-term investors who can hold through volatility until FDA approval and commercial launch, which could take 12-24 months. The stock's beta of 0.2 reduces market correlation, but its high idiosyncratic risk makes short-term trading extremely risky. Given the binary nature of the FDA decision, a minimum holding period of 12 months is recommended to capture the catalyst. For long-term investors, the potential upside to $178 justifies the risk, but position sizing should be conservative.